The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients
Authors:
- Satoru MiuraSMSatoru Miura
- Kyoichi KairaKKKyoichi Kaira
- Rieko KairaRKRieko Kaira
- Hiroaki AkamatsuHAHiroaki Akamatsu
- Akira OnoAOAkira Ono
- Takehito ShukuyaTSTakehito Shukuya
- Asuka TsuyaATAsuka Tsuya
- Yukiko NakamuraYNYukiko Nakamura
- Hirotsugu KenmotsuHKHirotsugu Kenmotsu
- Tateaki NaitoTateaki Naito
- Haruyasu MurakamiHMHaruyasu Murakami
- Toshiaki TakahashiTTToshiaki Takahashi
- 7 April 2015
- journal article
- case report
- Published by Springer Nature in Investigational New Drugs
- Vol. 33 (3) , 755-760
Abstract
Background Central nervous system (CNS) metastases caused by small-cell lung cancer (SCLC) are incurable and therefore fatal. Although such metastases are usually treated with chemotherapy or radiotherapy, their sensitivity to these treatment measures is unclear. Amrubicin appears to be a promising agent for relapsed SCLC, but its effectiveness in CNS metastases originating from SCLC is unknown. Methods Between April 2002 and December 2009, 110 SCLC patients with CNS metastasis were treated at Shizuoka Cancer Center. Of these, we retrospectively reviewed 8 consecutive cases with CNS metastases originating from relapsed SCLC that were treated with amrubicin as a second-line therapy. Results We recorded three sensitive relapses and five refractory cases. Amrubicin yielded a CNS response rate of 50 % (2 partial responses and 2 complete response; 95 % CI, 21.5–78.5 %) and the disease control rate for CNS lesions was 87.5 % (95 % CI, 52.9–97.8 %). All of the sensitive relapse patients achieved a partial response. The median time to progression for CNS metastases was 150.5 days (95 % CI, 9–171 days), and the median survival time from the start of amrubicin administration was 230.5 days (95 % CI, 89–619 days). We also report a dramatic improvement in one patient’s radiological result of intramedullary spinal cord metastasis and alleviation of her symptoms following amrubicin monotherapy including this case series. Conclusions The results of this study suggest that amrubicin is active in patients with CNS metastases originating from SCLC.Keywords
This publication has 21 references indexed in Scilit:
- Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402Journal of Clinical Oncology, 2008
- Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung AdenocarcinomaJournal of Thoracic Oncology, 2008
- An Update on the Treatment of CNS Metastases in Small Cell Lung CancerThe Cancer Journal, 2008
- Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301Journal of Clinical Oncology, 2006
- Phase III Trial Comparing Supportive Care Alone With Supportive Care With Oral Topotecan in Patients With Relapsed Small-Cell Lung CancerJournal of Clinical Oncology, 2006
- Metastasis to nervous system: spinal epidural and intramedullary metastasesJournal of Neuro-Oncology, 2005
- Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiationEuropean Journal of Cancer, 2002
- Identification of prognostic factors in patients with brain metastases: a review of 1292 patientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Intracranial metastases in small cell carcinoma of the lung prognostic aspectsCancer, 1983
- The palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology groupInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1980